Nucleic acid drugs represent a groundbreaking frontier in biopharmaceutics, offering innovative approaches to treat various diseases at the genetic level. These drugs harness the power of nucleic acids, such as RNA and DNA, to target specific genes associated with illnesses. In the realm of biopharmaceutics, nucleic acid drugs hold immense potential for precision medicine, allowing tailored treatments based on individual genetic profiles.
The development of nucleic acid drugs has opened avenues for tackling genetic disorders, cancers, and infectious diseases with unprecedented precision. Their mechanism involves modulating gene expression, silencing harmful genes, or correcting genetic mutations. Despite initial challenges, advancements in delivery systems and formulations have enhanced the stability and bioavailability of nucleic acid drugs.
Biopharmaceutics researchers are actively exploring the therapeutic possibilities of antisense oligonucleotides, siRNA, and gene-editing technologies. As these nucleic acid drugs progress through clinical trials, they signify a paradigm shift in personalized medicine and hold promise for transforming the landscape of biopharmaceutical interventions.
Vladlen Slepak
University of Miami, United States
Yong Xiao Wang
Albany Medical College, United States
Axel H Schonthal
University of Southern California, United States
Consolato M Sergi
Universities of Alberta and Ottawa, Canada
Madhav Bhatia
University of Otago, New Zealand
Luis Jesus Villarreal Gomez
Universidad Autónoma de Baja California, Mexico
Saad Tayyab
UCSI University, Malaysia
Anil Pareek
Anand Pharmacy College, India
Lan Wang
Paretor LLC, United States
Helen Cho
Samyang Biopharm Corporation, Korea, Republic ofSubmit your abstract Today
Title : Hepatotoxic botanicals-shadows of pearls
Consolato M Sergi, Universities of Alberta and Ottawa, Canada
Title : Development of novel drug delivery pathways enabled by perillyl alcohol (NEO100), A monoterpene with multifaceted biomedical applications
Axel H Schonthal, University of Southern California, United States
Title : From marker to mechanism: Ligand discovery enables functional analysis of OR51E1, an ectopic olfactory receptor, in prostate cancer
Vladlen Slepak, University of Miami, United States
Title : The impact of metal-decorated polymeric nanodots on proton relaxivity
Paulo Cesar De Morais, Catholic University of Brasilia, Brazil
Title : Principles and standards for managing healthcare transformation towards personalized, preventive, predictive, participative precision medicine ecosystems
Bernd Blobel, University of Regensburg, Germany
Title : Personalized and Precision Medicine (PPM) as a unique healthcare model based on design-inspired biotech- & biopharma-driven applications to secure the human healthcare and biosafety
Sergey Suchkov, N D Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences & InMedStar, Russian Federation
Title : R&D consultancy at the medicines discovery catapult: De-risking drug discovery for innovators
Adriana Gambardella, Medicine Discovery Catapult, United Kingdom
Title : Biocompatible synthesis of non crystalline iron oxide nanoparticles with stable colloidal properties
Lan Wang, Paretor LLC, United States
Title : Hydrogen sulfide in sepsis: From bench to bedside
Madhav Bhatia, University of Otago, New Zealand
Title : Biocompatibility and subcutaneous host response to silk fibroin–chitosan composite plugs: Progress toward biodegradable implant materials
Luis Jesus Villarreal Gomez, Universidad Autónoma de Baja California, Mexico